md-medicaldata

Authors

 

Milan Špuran¹, Anita Agić², Davor Korčok², Vladan Đorđević<sup>3,4

1</sup>Clinic for Gastroenterology, Clinical Center of Serbia, Belgrade, Serbia
²Abela Pharm, Belgrade, Serbia
³Clinic for Psychiatric Disorders “Dr Laza Lazarević” Belgrade, Serbia
⁴Faculty of Pharmacy and Health, University in Travnik, Bosnia and Herzegovina

 

Rad je primljen 13.08.2017. / Prihvaćen 24.08.2017

 

Correspondence to

Dr. Vladan Đorđević, PhD,
Clinic for Psychiatric Disorders
„Dr Laza Lazarević”
Višegradska 26, 11 000 Belgrade, Serbia
Tel: +381 61 611-64-75
e-mail: drvladandjordjevic@gmail.com

 

 

Abstract

 

Background/purpose: One of the most important probiotic monocultures is Saccharomyces boulardii, which is recommended for use in case of diarrhea, prevention of antibiotic-associated diarrhea, and prevention of Clostridium difficile-associated diarrhea. Bulardi® (Abela Pharm, Belgrade, Serbia) is a dietary supplement that contains 5 billion colony forming units per one capsule. The aim of study was to examine the use of probiotic monoculture Saccharomyces boulardii in maintaining the health of digestive system. Patients and Methods: The study was conducted as a clinical study on 3 144 respondents. Saccharomyces boulardii was applied equally in both genders, in all age groups of respondents, but most usually between 31 and 50 years old. Results: The most common indication for prescribing Saccharomyces boulardii were diarrheal syndrome, antibiotic-associated diarrhea, and eradication of Helycobacter pylori infection. The most patients had other diagnoses, like blood, blood-forming organs and immune disorders, diseases of the endocrine system, as well as diseases of the genitourinary system. Monoculture probiotic Saccharomyces boulardii is commonly used for 2 to 4 weeks, in a dose of 1 capsule per day, or as needed. In most of the respondents there was an improvement of symptoms. Conclusion: In most of the patients there was an improvement of symptoms, and considering that most of the respondents had multiple diagnoses, the fact that the probiotic had no side effects among patients indicates that is safe and effective for use in patients whose health is damaged by diseases that are not related to the digestive system.

 

 

 

Key words:

digestive diseases, diarrhea, probiotic monoculture, Saccharomyces boulardi.

 

 

Sažetak

 

Uvod/cilj. Jedna od najznačajnijih probiotskih monokultura je Saccharomyces boulardii, koja se preporučuje u slučaju dijareje, prevenciji antibiotske dijareje, kao i prevenciji dijareje uzrokovane Clostridium difficile. Bulardi® (Abela Pharm, Beograd, Srbija) je dijetetski suplement koji sadrži 5 milijardi kultura po kapsuli. Cilj istraživanja bio je da se ispita efikasnost upotrebe probiotske monokulture Saccharomyces boulardii u očuvanju zdravlja digestivnog trakta. Pacijenti i metod. Istraživanje je sprovedeno kao klinička studija na 3 144 ispitanika. Saccharomyces boulardii je primenjen pojednako kod oba pola, u svim starosnim grupama ispitanika, ali najviše u starosnom dobu od 31 do 50 godina. Rezultati. Najčešća indikacija za ordiniranje Saccharomyces boulardii bio je dijarejni sindrom, antibiotska dijareja i eradikacija infekcije Helicobacter pylori. Većina ispitanika je imala i druge dijagnoze, a najčešće poremećaje krvi, krvotvornih organa i imuniteta, bolesti endokrinog sistema, kao i bolesti genitourinarnog sistema. Probiotska monokultura Saccharomyces boulardii je najčešće korišćena 2 do 4 nedelje, u dozi od jedne kapsule dnevno, ili po potrebi. Kod većine ispitanika došlo je do poboljšanja simptoma. Zaključak. Kod većine ispitanika došlo je do poboljšanja simptoma, a uzimajući u obzir da je većina ispitanika imala više dijagnoza, činjenica da probiotik nema neželjenih efekata kod pacijenata ukazuje na njegovu bezbednu i efikasnu primenu kod pacijenata kojima je zdravlje narušeno bolestima koje nisu samo u vezi sa digestivnim sistemom.

 

 

Ključne reči:

digestivne bolesti, dijareja, probiotska monokultura, Saccharomyces boulardi.

 

 

References

 

1. Report on infectious diseases in the Republic of Serbia for 2014. Institute for Public Health ”Dr Milan Jovanovic Batut”, 2015. Available on: http://www.batut.org.rs/download/izvestaji/Izvestaj%20o%20zaraznim%20bolestima%202014.pdf
2. 2. Czerucka D, Piche T, Rampal P. Review article: yeast as probiotic - Saccharomyces boulardii.       Aliment Pharmacol Ther 2007; 26(83):767-78.
3. Szajewska H, Kolodziej M.  Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2015; 42(4):793-801.
4. Szajewska H, Horvat A, Kolodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2015; 41(5):1237-45.
5. 5. Kelesidis T. et al.  Efficacu and safety Saccharomyces boulardii for prevention and therapy of       gastrointestinal disorders. Ther Adv Gastroenterol 2012; 5(2):111-25.
6. 6.  Floch M, Walker A, Nieuwdorp M, Kim A, Brenner D, Qamar A, et al. Recommendations for Probiotic      Use-2015 Update: Proceedings and Consensus Opinion. J Clin Gastroenterol 2015; 46:S69-73.
7. Institute for public health of Serbia „Dr Milan Jovanovic Batut”. Republic of Serbia - Selected health indicators for 2005. Belgrade, 2007.
8. Ministry of Health and Institute for Public Health of Serbia  „Dr Milan Jovanovic Batut”.  The results of studies of health of the population Serbia - 2013. Belgrade, 2014.

UDK: 615.246
COBISS.SR-ID 245425932

PDF Špuran M. et al • MD-Medical Data 2017;9(3): 167-170